#USA #Salt Lake City #Molecular Diagnostics #Co-Diagnostics #CODX

Co-Diagnostics Announces Q3 2026 Earnings Release Date

On November 5, 2026, Co-Diagnostics, Inc. (Nasdaq: CODX), a leading player in the field of molecular diagnostics, disclosed a change regarding its upcoming earnings report. Originally scheduled for November 12, 2026, the financial results for the third quarter of 2026 will now be released on November 10, 2026, after the stock market closes.

This shift aims to ensure that investors and stakeholders receive timely information about the company’s financial performance. The announcement reflects Co-Diagnostics' commitment to maintain transparency with its investors, allowing them to better anticipate market reactions and make informed decisions.

Alongside this announcement, Co-Diagnostics will conduct a conference call and webcast on the day of the earnings release, starting at 4:30 PM Eastern Time. This session aims to provide investors and analysts with an in-depth understanding of the company’s financial results and future outlook, discussing various aspects of their operational efficiencies, financial health, and business strategy moving forward.

Accessing the Webcast

The conference call will be accessible not only through a dedicated webcast page on their website Event Webcasts but also through direct dial-in options available for participants. Investors can join the call by dialing 1-888-880-3330 for toll-free access or 1-646-357-8766 for those calling from other locations. For individuals unable to participate live, the call will be recorded and made available for listening later at Co-Diagnostics' official website.

About Co-Diagnostics

Co-Diagnostics, Inc., headquartered in Salt Lake City, Utah, specializes in the development and manufacturing of innovative molecular diagnostics technologies. With a unique and patented platform, Co-Diagnostics designs diagnostic tests focusing on the detection and analysis of nucleic acid molecules, which play a critical role in identifying a variety of health conditions. The company's wider applications extend to developing specific tests for its proprietary Co-Dx PCR platform, designed for personal and point-of-care use.

By harnessing its proprietary technology, Co-Diagnostics endeavors to enhance its offerings in the diagnostics market, identifying genetic markers, and creating tests tailored for various diseases beyond infectious conditions. As the company continues to grow, staying current with developments like these earnings announcements is crucial for investors tracking Co-Diagnostics’ progress and innovations.

Conclusion

Co-Diagnostics’ proactive approach in rescheduling their earnings announcement demonstrates its dedication to its shareholders. The upcoming conference call presents an excellent opportunity for investors to gain valuable insights into the company’s performance and strategic direction. Stakeholders are encouraged to tune in to ensure they remain well-informed as Co-Diagnostics continues to push the envelope in molecular diagnostics.

For further updates regarding the company’s operations and product developments, stakeholders can monitor the Co-Diagnostics investor relations page or follow their official communication channels.

Keeping abreast of such updates is fundamental to staying informed about one of the promising players in the molecular diagnostics industry.